As for metastatic HER2-positive breast cancer, a double-blind, phase 3 trial proved that the combination of pertuzumab, trastuzumab and docetaxel prolonged the survival period compared with the control group (placebo, trastuzumab and docetaxel) [23]. Here, ERBB2 is linked to breast cancer.